GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 112 filers reported holding GENMARK DIAGNOSTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $6,235,000 | +57.8% | 260,902 | -3.6% | 0.00% | 0.0% |
Q4 2020 | $3,952,000 | +3.4% | 270,673 | +0.5% | 0.00% | 0.0% |
Q3 2020 | $3,823,000 | -22.1% | 269,247 | -19.3% | 0.00% | 0.0% |
Q2 2020 | $4,908,000 | +393.8% | 333,622 | +38.3% | 0.00% | – |
Q1 2020 | $994,000 | -14.5% | 241,259 | -0.1% | 0.00% | – |
Q4 2019 | $1,162,000 | -18.5% | 241,483 | +2.6% | 0.00% | – |
Q3 2019 | $1,425,000 | -3.5% | 235,326 | +3.5% | 0.00% | – |
Q2 2019 | $1,477,000 | -12.9% | 227,443 | -4.9% | 0.00% | – |
Q1 2019 | $1,696,000 | +50.1% | 239,173 | +2.8% | 0.00% | – |
Q4 2018 | $1,130,000 | -28.9% | 232,611 | +7.5% | 0.00% | – |
Q3 2018 | $1,590,000 | +14.6% | 216,332 | -0.6% | 0.00% | – |
Q2 2018 | $1,388,000 | +8.9% | 217,575 | -7.2% | 0.00% | – |
Q1 2018 | $1,275,000 | +26.2% | 234,349 | -3.3% | 0.00% | – |
Q4 2017 | $1,010,000 | -57.5% | 242,344 | -1.9% | 0.00% | -100.0% |
Q3 2017 | $2,379,000 | -9.9% | 246,960 | +10.7% | 0.00% | 0.0% |
Q2 2017 | $2,641,000 | +0.5% | 223,163 | +8.9% | 0.00% | 0.0% |
Q1 2017 | $2,627,000 | +8.2% | 204,928 | +3.3% | 0.00% | 0.0% |
Q4 2016 | $2,429,000 | +17.2% | 198,446 | +13.0% | 0.00% | 0.0% |
Q3 2016 | $2,073,000 | +28.4% | 175,631 | -5.4% | 0.00% | – |
Q2 2016 | $1,614,000 | +68.7% | 185,657 | +2.2% | 0.00% | – |
Q1 2016 | $957,000 | -34.7% | 181,658 | -3.8% | 0.00% | – |
Q4 2015 | $1,465,000 | +6.8% | 188,796 | +8.3% | 0.00% | – |
Q3 2015 | $1,372,000 | -29.5% | 174,381 | -18.8% | 0.00% | -100.0% |
Q2 2015 | $1,945,000 | -24.9% | 214,664 | +7.6% | 0.00% | 0.0% |
Q1 2015 | $2,590,000 | -4.7% | 199,526 | -0.1% | 0.00% | 0.0% |
Q4 2014 | $2,717,000 | +56.1% | 199,632 | +2.9% | 0.00% | – |
Q3 2014 | $1,740,000 | -63.4% | 193,939 | -44.8% | 0.00% | -100.0% |
Q2 2014 | $4,752,000 | +169.1% | 351,268 | +97.7% | 0.00% | – |
Q1 2014 | $1,766,000 | -35.4% | 177,647 | -13.7% | 0.00% | -100.0% |
Q4 2013 | $2,735,000 | -21.5% | 205,773 | -28.3% | 0.00% | 0.0% |
Q3 2013 | $3,486,000 | +188.1% | 287,138 | +145.6% | 0.00% | – |
Q2 2013 | $1,210,000 | – | 116,933 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
NEEDHAM INVESTMENT MANAGEMENT LLC | 1,443,400 | $5,947,000 | 1.68% |
Casdin Capital, LLC | 3,365,000 | $13,864,000 | 1.47% |
Lyon Street Capital, LLC | 191,656 | $790,000 | 1.26% |
CADIAN CAPITAL MANAGEMENT, LP | 3,489,055 | $14,375,000 | 0.71% |
Portolan Capital Management | 893,090 | $3,680,000 | 0.55% |
Eversept Partners, LP | 524,257 | $2,159,939 | 0.54% |
Bullseye Asset Management LLC | 78,961 | $325,000 | 0.39% |
Parkman Healthcare Partners LLC | 200,000 | $824,000 | 0.38% |
Granite Investment Partners, LLC | 757,878 | $3,122,000 | 0.20% |
Bellevue Group AG | 2,411,926 | $9,937,000 | 0.19% |